UPF1 Inhibits Hepatocellular Carcinoma Growth through DUSP1/p53 Signal Pathway
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Suman | - |
dc.contributor.author | Hwang, Yukyung | - |
dc.contributor.author | Kim, Tae Hun | - |
dc.contributor.author | Jeong, Jaemin | - |
dc.contributor.author | Choi, Dongho | - |
dc.contributor.author | Hwang, Jungwook | - |
dc.date.accessioned | 2022-07-06T06:23:29Z | - |
dc.date.available | 2022-07-06T06:23:29Z | - |
dc.date.created | 2022-05-04 | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138954 | - |
dc.description.abstract | Human hepatocellular carcinoma (HCC) has a high mortality rate because of the dearth of effective treatments. Multiple studies have shown that overexpression of UPF1, a key nonsense-mediated mRNA decay (NMD) factor, reduces HCC growth through various cell signaling pathways. However, the mechanism by which UPF1 expression retards HCC proliferation through the regulation of RNA stability remains unclear. By employing various UPF1 variants and transcriptome analysis, we revealed that overexpression of UPF1 variants, not UPF1-mediated NMD, reduces HCC tumorigenesis. Additionally, UPF1 variant overexpression reduced tumorigenesis in xenografted mice. Transcriptome analysis indicated that the level of dual specificity phosphatase 1 (DUSP1) was increased by UPF1 variants via posttranscriptional regulation. The UPF1 overexpression-mediated increase of DUSP1 activated tumor suppressor signaling, ultimately inhibiting cell growth. In this study, we highlighted the function of UPF1 as a tumor suppressor in HCC growth. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | UPF1 Inhibits Hepatocellular Carcinoma Growth through DUSP1/p53 Signal Pathway | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Dongho | - |
dc.contributor.affiliatedAuthor | Hwang, Jungwook | - |
dc.identifier.doi | 10.3390/biomedicines10040793 | - |
dc.identifier.scopusid | 2-s2.0-85128501960 | - |
dc.identifier.wosid | 000786018100001 | - |
dc.identifier.bibliographicCitation | BIOMEDICINES, v.10, no.4, pp.1 - 12 | - |
dc.relation.isPartOf | BIOMEDICINES | - |
dc.citation.title | BIOMEDICINES | - |
dc.citation.volume | 10 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 12 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | MESSENGER-RNA DECAY | - |
dc.subject.keywordPlus | CANCER PROGRESSION | - |
dc.subject.keywordPlus | TRANSCRIPTOME | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | STRINGTIE | - |
dc.subject.keywordPlus | HISAT | - |
dc.subject.keywordPlus | NMD | - |
dc.subject.keywordAuthor | UPF1 | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | posttranscriptional regulation | - |
dc.subject.keywordAuthor | DUSP1 | - |
dc.identifier.url | https://www.mdpi.com/2227-9059/10/4/793 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.